Related Experiment Video

Updated: Jul 8, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Treatment of chronic hepatitis B in children

Aydan Kansu1

  • 1Pediatric Gastroenterology Department, Ankara University School of Medicine, Ankara, Turkey. aydankansu@gmail.com

Recent Patents on Anti-Infective Drug Discovery
|January 29, 2008
PubMed

Insights

Chronic hepatitis B in children requires treatment to prevent severe complications like cirrhosis. Current options, interferon-alpha (IFN-alpha) and lamivudine (LAM), show moderate effectiveness but require further research for optimal pediatric strategies.

Area of Science:

  • Pediatric Gastroenterology and Hepatology
  • Virology and Immunology
  • Pharmacology and Therapeutics

Background:

  • Chronic hepatitis B (CHB) in children is often asymptomatic but carries a lifelong risk of severe complications, including cirrhosis and hepatocellular carcinoma (HCC).
  • Effective antiviral therapies are crucial for suppressing the hepatitis B virus (HBV) and preventing disease progression in pediatric patients.
  • Current treatment guidelines aim to improve long-term survival and reduce the incidence of liver-related morbidity.

Purpose of the Study:

  • To review and compare the efficacy and safety of current therapeutic options for chronic hepatitis B in children.
  • To identify predictors of treatment response for interferon-alpha (IFN-alpha) and lamivudine (LAM).
  • To discuss the limitations of existing treatments and the need for novel therapeutic strategies in pediatric HBV management.

Main Methods:

  • Review of existing literature on interferon-alpha (IFN-alpha) and lamivudine (LAM) therapy in pediatric chronic hepatitis B.
  • Analysis of reported virologic response rates, sustained responses, and seroconversion rates for both agents.
  • Evaluation of adverse event profiles and drug resistance patterns associated with IFN-alpha and LAM monotherapy and combination treatments.

Main Results:

  • Interferon-alpha (IFN-alpha) demonstrated a 30-40% virologic response rate with sustained response in 85-90% of responders, but carries risks of side effects including bone marrow suppression and psychiatric issues.
  • Lamivudine (LAM) achieved a 20-30% virologic response rate and 56-80% HBeAg seroconversion, with increased rates upon longer treatment duration, but carries a risk of viral resistance and mutations.
  • Combination therapies of IFN-alpha and LAM did not show significant superiority over monotherapy in pediatric patients.

Conclusions:

  • Neither IFN-alpha nor LAM has emerged as a definitive best treatment for chronic hepatitis B in children.
  • Predictors of response for both therapies include high ALT levels, low HBVDNA levels, and high histological activity index.
  • Further research into new drugs and innovative treatment strategies is essential to optimize the management of pediatric chronic hepatitis B.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...